These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1001 related articles for article (PubMed ID: 10910142)

  • 1. A phase I-II trial to examine the toxicity of CMV- and EBV-specific cytotoxic T lymphocytes when used for prophylaxis against EBV and CMV disease in recipients of CD34-selected/T cell-depleted stem cell transplants.
    Lucas KG; Sun Q; Burton RL; Tilden A; Vaughan WP; Carabasi M; Salzman D; Ship A
    Hum Gene Ther; 2000 Jul; 11(10):1453-63. PubMed ID: 10910142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneous ex vivo expansion of cytomegalovirus and Epstein-Barr virus-specific cytotoxic T lymphocytes using B-lymphoblastoid cell lines expressing cytomegalovirus pp65.
    Sun Q; Pollok KE; Burton RL; Dai LJ; Britt W; Emanuel DJ; Lucas KG
    Blood; 1999 Nov; 94(9):3242-50. PubMed ID: 10556213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. B lymphoblastoid cell lines as efficient APC to elicit CD8+ T cell responses against a cytomegalovirus antigen.
    Sun Q; Burton RL; Dai LJ; Britt WJ; Lucas KG
    J Immunol; 2000 Oct; 165(7):4105-11. PubMed ID: 11034422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation of trispecific cytotoxic T cells recognizing cytomegalovirus, adenovirus, and Epstein-Barr virus: an approach for adoptive immunotherapy of multiple pathogens.
    Karlsson H; Brewin J; Kinnon C; Veys P; Amrolia PJ
    J Immunother; 2007; 30(5):544-56. PubMed ID: 17589295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expansion of T cells targeting multiple antigens of cytomegalovirus, Epstein-Barr virus and adenovirus to provide broad antiviral specificity after stem cell transplantation.
    Hanley PJ; Shaffer DR; Cruz CR; Ku S; Tzou B; Liu H; Demmler-Harrison G; Heslop HE; Rooney CM; Gottschalk S; Bollard CM
    Cytotherapy; 2011 Sep; 13(8):976-86. PubMed ID: 21539497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adenovirally transduced dendritic cells induce bispecific cytotoxic T lymphocyte responses against adenovirus and cytomegalovirus pp65 or against adenovirus and Epstein-Barr virus EBNA3C protein: a novel approach for immunotherapy.
    Hamel Y; Blake N; Gabrielsson S; Haigh T; Jooss K; Martinache C; Caillat-Zucman S; Rickinson AB; Hacein-Bey S; Fischer A; Cavazzana-Calvo M
    Hum Gene Ther; 2002 May; 13(7):855-66. PubMed ID: 11975851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A single exercise bout enhances the manufacture of viral-specific T-cells from healthy donors: implications for allogeneic adoptive transfer immunotherapy.
    Spielmann G; Bollard CM; Kunz H; Hanley PJ; Simpson RJ
    Sci Rep; 2016 May; 6():25852. PubMed ID: 27181409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of suitable target antigens and immunoassays for high-accuracy immune monitoring of cytomegalovirus and Epstein-Barr virus-specific T cells as targets of interest in immunotherapeutic approaches.
    Tischer S; Dieks D; Sukdolak C; Bunse C; Figueiredo C; Immenschuh S; Borchers S; Stripecke R; Maecker-Kolhoff B; Blasczyk R; Eiz-Vesper B
    J Immunol Methods; 2014 Jun; 408():101-13. PubMed ID: 24877879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of Epstein-Barr virus nuclear antigen 1, 3 and lytic antigen BZLF1 peptide pools allows fast and efficient stimulation of Epstein-Barr virus-specific T cells for adoptive immunotherapy.
    Wang Y; Aïssi-Rothe L; Virion JM; De Carvalho Bittencourt M; Ulas N; Audonnet S; Salmon A; Clement L; Venard V; Jeulin H; Stoltz JF; Decot V; Bensoussan D
    Cytotherapy; 2014 Jan; 16(1):122-34. PubMed ID: 24094498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ex vivo expansion and prophylactic infusion of CMV-pp65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation.
    Micklethwaite K; Hansen A; Foster A; Snape E; Antonenas V; Sartor M; Shaw P; Bradstock K; Gottlieb D
    Biol Blood Marrow Transplant; 2007 Jun; 13(6):707-14. PubMed ID: 17531781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytomegalovirus-specific cytolytic T-cell lines and clones generated against adenovirus-pp65-infected dendritic cells.
    Keever-Taylor CA; Margolis D; Konings S; Sandford GR; Nicolette CA; Lawendowski C; Burns WH
    Biol Blood Marrow Transplant; 2001; 7(5):247-56. PubMed ID: 11400946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytomegalovirus-specific cytotoxic T lymphocytes can be efficiently expanded from granulocyte colony-stimulating factor-mobilized hemopoietic progenitor cell products ex vivo and safely transferred to stem cell transplantation recipients to facilitate immune reconstitution.
    Clancy LE; Blyth E; Simms RM; Micklethwaite KP; Ma CK; Burgess JS; Antonenas V; Shaw PJ; Gottlieb DJ
    Biol Blood Marrow Transplant; 2013 May; 19(5):725-34. PubMed ID: 23380344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ex vivo generation of effective Epstein-Barr virus (EBV)-specific CD8+ cytotoxic T lymphocytes from the peripheral blood of immunocompetent Epstein Barr virus-seronegative individuals.
    Metes D; Storkus W; Zeevi A; Patterson K; Logar A; Rowe D; Nalesnik MA; Fung JJ; Rao AS
    Transplantation; 2000 Nov; 70(10):1507-15. PubMed ID: 11118098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CMV-, EBV- and ADV-specific T cell immunity: screening and monitoring of potential third-party donors to improve post-transplantation outcome.
    Sukdolak C; Tischer S; Dieks D; Figueiredo C; Goudeva L; Heuft HG; Verboom M; Immenschuh S; Heim A; Borchers S; Mischak-Weissinger E; Blasczyk R; Maecker-Kolhoff B; Eiz-Vesper B
    Biol Blood Marrow Transplant; 2013 Oct; 19(10):1480-92. PubMed ID: 23891747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid generation of CMV pp65-specific T cells for immunotherapy.
    Bao L; Sun Q; Lucas KG
    J Immunother; 2007; 30(5):557-61. PubMed ID: 17589296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adoptive transfer of cytotoxic T lymphocytes for the treatment of transplant-associated lymphoma.
    Boyle TJ; Berend KR; DiMaio JM; Coles RE; Via DF; Lyerly HK
    Surgery; 1993 Aug; 114(2):218-25; discussion 226. PubMed ID: 8393595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-associated post-transplant lymphomas.
    Liu Z; Savoldo B; Huls H; Lopez T; Gee A; Wilson J; Brenner MK; Heslop HE; Rooney CM
    Recent Results Cancer Res; 2002; 159():123-33. PubMed ID: 11785836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytolytic T cell reactivity to Epstein-Barr virus is lost during in vitro T cell expansion.
    Carlens S; Liu D; Ringdén O; Aschan J; Christensson B; Levitsky V; Dilber MS
    J Hematother Stem Cell Res; 2002 Aug; 11(4):669-74. PubMed ID: 12201955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects.
    Berencsi K; Gyulai Z; Gönczöl E; Pincus S; Cox WI; Michelson S; Kari L; Meric C; Cadoz M; Zahradnik J; Starr S; Plotkin S
    J Infect Dis; 2001 Apr; 183(8):1171-9. PubMed ID: 11262198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antigenic competition in the generation of multi-virus-specific cell lines for immunotherapy of human cytomegalovirus, polyomavirus BK, Epstein-Barr virus and adenovirus infection in haematopoietic stem cell transplant recipients.
    Roubalová K; Němečková Š; Kryštofová J; Hainz P; Pumannová M; Hamšíková E
    Immunol Lett; 2020 Dec; 228():64-69. PubMed ID: 33031870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 51.